Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus

Kidney International

Volumn 83, Issue 2, 2013, Pages 278-284

  Wong, Muh Geot ^a   Perkovic, Vlado ^b   Woodward, Mark ^b   Chalmers, John ^b   Li, Qiang ^b   Hillis, Graham S ^b   Yaghobian Azari, Dania ^a   Jun, Min ^b   Poulter, Neil ^c   Hamet, Pavel ^d   Williams, Bryan ^e   Neal, Bruce ^b   Mancia, Giuseppe ^f   Cooper, Mark ^g   Pollock, Carol A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f SAN GERARDO HOSPITAL   (Italy)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

albuminuria; chronic kidney failure; diabetic nephropathy

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE;

EID: 84873405796     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.383     Document Type: Article

References (44)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
3. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52: 1036-1040.
4. Fioretto P, Stehouwer CD, Mauer M et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998; 41: 233-236.
5. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
7. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009; 5: 375-383.
8. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 2006; 103: 7643-7648.
9. Sharma K, Jin Y, Guo J et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530.
10. Ziyadeh FN, Sharma K, Ericksen M et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93: 536-542.
11. Sharma K, Ziyadeh FN, Alzahabi B et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-859.
12. Hellmich B, Schellner M, Schatz H et al. Activation of transforming growth factor-beta1 in diabetic kidney disease. Metabolism 2000; 49: 353-359.
13. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21: 568-573.
14. Gould SE, Day M, Jones SS et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61: 51-60.
15. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta-dependent fibro-genesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284: F1006-F1013.
16. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
17. Zeisberg M, Bottiglio C, Kumar N et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-F1067.
18. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392-2399.
19. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037-2049.
20. Wang S, de Caestecker M, Kopp J et al. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006; 17: 2504-2512.
21. Dudas PL, Argentieri RL, Farrell FX. BMP-7 fails to attenuate TGF-beta1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol Dial Transplant 2009; 24: 1406-1416.
22. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
23. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
24. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696.
25. Boon MR, van der Horst G, van der Pluijm G et al. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 2011; 22: 221-229.
26. Bohle A, Mackensen-Haen S, von Gise H. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 1987; 7: 421-433.
27. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
28. Suthanthiran M, Li B, Song JO et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 3479-3484.
29. Suthanthiran M, Gerber LM, Schwartz JE et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009; 76: 72-80.
30. Zitouni K, Harry DD, Nourooz-Zadeh J et al. Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes. Kidney Int 2005; 67: 1993-1998.
31. August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl 2003; S99-104.
32. Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with longterm renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34: 818-823.
33. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359-369.
34. Sharma K, Ix JH, Mathew AV et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151.
35. Soma J, Sato K, Saito H et al. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2795-2799.
36. Soma J, Sugawara T, Huang YD et al. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002; 92: 693-698.
37. Lizakowski S, Tylicki L, Renke M et al. Aliskiren and perindopril reduce the levels of transforming growth factor-beta in patients with non-diabetic kidney disease. Am J Hypertens 2012; 25: 636-639.
38. Benigni A, Zoja C, Corna D et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824.
39. Collaborative Study Group (CSG) ELaC. Multicenter, phase 2 study to evaluate the safety and renal efficacy of LY2382770 in patients with diabetic kidney disease due to type 1 or type 2 diabetes. ClinicalTrials.gov Identifier NCT01113801; 2010.
40. Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol 2010; 55: 340-347.
41. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
42. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
43. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 6: 716-723.
44. Schwarz GE. Estimating the dimension of a model. Ann Statist 1978; 2: 461-464.